MRUS - Merus posts positive efficacy data from early-stage zenocutuzumab cancer study

Merus ([[MRUS]] +1.6%) announces positive interim efficacy data from the phase 1/2 eNRGy trial of bispecific antibody zenocutuzumab ((Zeno)) in patients with NRG1+ cancers.61 patients with NRG1+ cancer have been enrolled, including 45 patients evaluable for response as of the data cutoff date.Encouraging early clinical activity was observed, with confirmed responses in 5 of 12 patients with pancreatic cancer (42%) and in 13 of 45 patients across several NRG1+ tumor types (29%).Partial responses ((PRs)) were achieved across four different NRG1+ tumor types and multiple different fusion partners.Zeno showed a favorable and tolerable safety profile, and majority of adverse events were mild or moderate (Grade 1 or 2) in severity.Merus plans the next program and clinical update for Zeno at a major medical conference by the first half of 2022.#ASCO21

For further details see:

Merus posts positive efficacy data from early-stage zenocutuzumab cancer study